Drugs / LY2828360
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01319929 | Mar → Sep 2011 | osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2828360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01319929 ↗ |
| Action | Activate | “Cannabinoid CB2 receptor agonist” CHEMBL3139186 ↗ |
| Modality | Small molecule | — CHEMBL3139186 ↗ |
| Route | Oral | “Administered orally” NCT01319929 ↗ |
| Target | CNR2 | “Cannabinoid CB2 receptor agonist” CHEMBL3139186 ↗ |